Osteoarthritis Cell Composition With Size Control Against Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic compositions for osteoarthritis using chondrocytes often result in unpredictable therapeutic effects due to cell aggregation and difficulties in selecting appropriate cell sizes and types, leading to challenges in patient compliance and quality control during administration.
Innovation Solution
A pharmaceutical composition comprising transformed mammalian cells expressing TGF-β, with a particle diameter D90 of less than 200 μm, and untransformed mammalian cells with a D90 of less than 300 μm, minimizing cell aggregation and improving patient compliance and quality control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chondrocytes are used as therapeutic agents for osteoarthritis, then cartilage regeneration can be promoted, but cell aggregation occurs leading to unpredictable therapeutic effects and manufacturing difficulties
Solution Approach 1:
The patent applies parameter changes by strictly controlling cell size parameters (D10: 30-70 μm, D50: 70-120 μm, D90: 120-200 μm) and transformation efficiency (70-95%) to prevent aggregation and ensure consistent therapeutic effects. This quantitative control of cellular parameters resolves the contradiction between promoting cartilage regeneration and preventing unpredictable aggregation.
2Reliability
If transformed chondrocytes expressing TGF-β are used to enhance cartilage regeneration, then therapeutic efficacy is improved, but cell size control becomes more difficult leading to aggregation
Solution Approach 1:
The patent maintains manufacturing precision by controlling transformation efficiency within 70-95% and cell size within specific ranges (D10: 30-70 μm, D50: 70-120 μm, D90: 120-200 μm). This ensures that transformed chondrocytes expressing TGF-β achieve enhanced cartilage regeneration while preventing aggregation through strict size uniformity control.
3Ease of manufacture
If cell size is reduced to minimize aggregation, then manufacturing and administration become easier, but therapeutic effectiveness may be compromised
Solution Approach 1:
The patent optimizes cell size parameters to balance ease of manufacture and therapeutic effectiveness. By setting D10: 30-70 μm, D50: 70-120 μm, and D90: 120-200 μm, the invention ensures cells are small enough for easy handling and reduced aggregation while remaining large enough to maintain therapeutic effectiveness for cartilage regeneration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The selected cell mixture effectively treats osteoarthritis by reducing cell aggregation, enhancing therapeutic efficacy, and facilitating easy management in therapeutic agent manufacturing and administration, while providing significant pain relief and cartilage structural improvement in animal models.
Implementation Method 1
the TGF-β is known to be involved in proteoglycan synthesis, chondrocyte growth and tissue regeneration. Further, the TGF-β is also known to have immunosuppressive and anti-inflammatory functions.
Data Source
AI summary
A pharmaceutical composition for prevention or treatment of osteoarthritis according to an embodiment of the present disclosure includes cells or cell groups having a specific size or less. Mixed cells, which are selected to a specific size or less as an active ingredient of the present invention, of transformed mammalian cells with TGF-β and untransformed mammalian cells minimize aggregation between chondrocytes and have beneficial therapeutic effects. In addition, when administering the selected mixed cells having the specific size or less to a patient, patient compliance may be improved, and it is easy to manage quality in therapeutic agent manufacturing facilities or hospitals.